1) Fabre LF:Buspirone in the Management of major depression:A placebo-controlled comparison. J Clin Psychiatry 51(Suppl 9):55-61, 1999
2) Gammans RE, Mayol RF, LaBudde JA:Metabolism and disposition of buspirone. Am J Med 80(3B):41-51, 1986
3) Hensler GJ:Regulation of 5-HT1A receptor function in brain following agonist or antidepressant administration. Life Sciences 72:1665-1682, 2003
4) Howland RH:Biochemical and clinical effect of buspiron augmentation. J Clin Psychiatry 55:264, 1994
5) 岩本泰行,山脇成人:向精神薬による悪性症候群とセロトニン症候群―鑑別診断と治療の要点.臨精医 32:521-528,2003
6) 笠茂公弘:セディール(クエン酸タンドスピロン)による抗うつ薬の効果増強の試み.新薬と臨牀 49:1067-1071,2000
7) Masuda Y, Akagawa Y, Hishikawa Y:Effect of serotonin 1A agonist tandospirone on depression symptoms in senile patient with dementia. Hum Psychopharmacol Clin Exp 17:191-193, 2002
8) 西嶋康一:SSRIの副作用・相互作用.医薬ジャーナル 35:1335-1340,1999
9) 西嶋康一:タンドスピロンの単独投与によってうつ病の再発が抑制された1例.精神医学 42:399-401,2000
10) Rickels K, Amsterdam JD, Clary C, et al:Buspirone in major depression:A controlled study. J Clin Psychiatry 52:34-38, 1991
11) Sternbach H:The serotonin syndrome. Am J Psychiatry 148:705-713, 1991